Quaker Houghton KWR

Zacks Investment Research 10 nov

Innospec Inc. reported Q3 2026 adjusted EPS of $1.29, up 15.2% year-over-year and beating consensus estimates by 2.4%. Performance Chemicals saw operating income surge 83.7% driven by favorable pricing and product mix, while Oilfield Services grew 39.6% in operating income. However, revenues of $473.6 million missed estimates, and Fuel Specialties showed modest growth. The company ended the quarter debt-free with $251.9 million in cash.

Zacks Investment Research 2 nov

Quaker Chemical (KWR) reported Q3 adjusted EPS of $2.39, beating estimates by 10.6% with 14.9% year-over-year growth. Net sales rose 10.3% to $544.5 million, driven by 7% pricing improvements and 3% volume growth across all segments. However, operating cash flow declined significantly due to higher working capital outflows. Management expects sequential revenue and EBITDA declines in Q4 due to seasonal patterns and soft industrial activity in Asia.

Zacks Investment Research 29 oct

Quaker Chemical reported Q3 2026 earnings of $2.39 per share, beating consensus estimates of $2.16 and surpassing revenue expectations. However, the company received a Zacks Rank #3 (Hold) rating due to mixed estimate revisions, suggesting near-term performance in line with the market. The Chemical - Specialty industry ranks in the top 40% of Zacks industries.

Zacks Investment Research 23 oct

The Zacks Chemicals Specialty industry faces headwinds from weak demand in Europe and China, elevated input costs, and tariff disruptions, pressuring profit margins. However, three specialty chemical companies—Element Solutions, Perimeter Solutions, and Quaker Chemical—are implementing strategic cost-cutting and productivity measures to navigate the challenging environment. The industry ranks #166 out of 250 Zacks industries and has underperformed the S&P 500 over the past year, though valuations remain attractive relative to the broader market.

Zacks Investment Research 19 oct

Quaker Chemical (KWR) has earned a Zacks Momentum Style Score of A and a #2 (Buy) rating. The specialty chemical company demonstrates positive momentum with shares up 0.65% weekly and 20.26% annually, outperforming the S&P 500's 16.73% gain. Recent earnings estimate revisions have been positive, with 2 upward revisions and none downward over the past two months, boosting consensus estimates from $7.72 to $7.85.